Neglected Tropical Diseases: A Continuing Priority and a Lurking Threat

Neglected Tropical Diseases: A Continuing Priority and a Lurking Threat

Loading document ...
Page
of
Loading page ...

Author(s)

Author(s): Henry Benerman

Download Full PDF Read Complete Article

DOI: 10.18483/ijSci.1311 190 612 1-4 Volume 6 - Jul 2017

References

  1. Agency FEMA. About the Agency www.fema.gov 2016 [updated April 1, 2016; cited 2016 April 6, 2016]. Available from: https://www.fema.gov/about-agency.
  2. Salaam-Blyther T. Neglected Tropical Diseases: Background,
  3. Responses, and Issues for Congress. In: Service CR, editor. 2011.
  4. Aldridge S. Tropical Infectious Diseases. In: Lerner BW, Lerner KL, editors. Infectious Diseases: In Context: Gale; 2008. p. 834-6.
  5. Malaria GH-DoPDa. Neglected Tropical Diseases. Which diseases are considered Neglected Tropical Diseases? Centers for Disease Control and Prevention: Department of Health and Human Services; 2011.
  6. Oprea L, Braunack-Mayer A, Gericke CA. Ethical issues in funding research and development of drugs for neglected tropical diseases. Journal of Medical Ethics: BMJ Publishing Group; 2009. p. 310-4.
  7. Trouiller P, Olliaro P, Torreele E, Orbinski J, Liang R, Ford N. Drug Development of neglected diseases. a deficient market and a public-health policy failure. The Lancet: Elsevier Inc.; 2002. p. 2188-94.
  8. Organization WH. Chagas disease (American trypanosomiasis) Fact Sheet. World Health Organization2016.
  9. Albon CR. Infectious Diseases Threaten National Security. Do Infectious Diseases Pose a Threat? Current Intelligence: Greenhaven Press; 2014.
  10. Frischknecht F. The history of biological warfare. EMBO Reports: The European Molecular Biology Organization; 2003. p. S47-S52.
  11. Burn C, Montgomery SP. An Estimate of the Burden of Chagas Disease in the United States. Clinical Infectious Diseases: Oxford Journals; 2009.
  12. Control CfD. Parasites-American Trypanosomiasis (also known as Chagas Disease). Triatomine Bug FAQs: United States Department of Health and Human Services; 2016.
  13. Barder O, Kremer M, Williams H. Advance Market Commitments. A Policy to Stimulate Investment in Vaccines for Neglected Diseases. Economists' Voice: The Berkeley Electronic Press; 2006. p. 1-6.
  14. Handfield R, Feldstein J. Insurance Companies' Perspectives on the Orphan Drug Pipeline. American Health & Drug Benefits2013. p. 589-97.
  15. Newton-Sanchez, O. A. Seroprevalence of Trypanosoma cruzi (TC) and risk factors in Colima, Mexico. Gaceta Medica de Mexico S; 2013. p.0016-3813.

Cite this Article:

  • BibTex
  • RIS
  • APA
  • Harvard
  • IEEE
  • MLA
  • Vancouver
  • Chicago

International Journal of Sciences is Open Access Journal.
This article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.
Author(s) retain the copyrights of this article, though, publication rights are with Alkhaer Publications.

Search Articles

Issue May 2019

Volume 8, May 2019


Table of Contents


Order Print Copy

World-wide Delivery is FREE

Share this Issue with Friends:


Submit your Paper